Results 211 to 220 of about 5,297,540 (313)

The role of neoadjuvant therapy in elderly patients with T1b-T2N + esophageal cancer: a population-based cohort study. [PDF]

Discov Oncol
Lin JP, Hong JH, Zhuang FN, He H, Chen YJ, Liu SY, Wang F.   +6 more
europepmc   +1 more source

The impact of time‐to‐recurrence on post‐recurrence mortality in stage I–III colorectal cancer: A nationwide Danish cohort study

International Journal of Cancer, EarlyView.
What's New? Colorectal cancer (CRC) recurrence is a significant threat to survival despite surgery with curative intent. The characteristics of CRC recurrence, however, remain poorly understood, challenging postoperative surveillance. This study investigated post‐recurrence mortality and associations between time‐to‐recurrence and mortality among stage
Jesper Nors, Kåre Andersson Gotschalck, Rune Erichsen, Claus Lindbjerg Andersen   +3 more
wiley   +1 more source

The effect of neoadjuvant therapy on radiological, surgical, and pathological results in nonmetastatic breast cancer: A retrospective observational study. [PDF]

Medicine (Baltimore)
Çorapli M, Alakuş H.
europepmc   +1 more source

A multilevel perspective on MSH6‐associated Lynch syndrome: Integrating molecular, biological, and clinical insights

International Journal of Cancer, EarlyView.
Abstract Lynch syndrome (LS) is the most common hereditary colorectal cancer syndrome, caused by a germline pathogenic variant in one of the mismatch repair (MMR) genes. Among these, MSH6‐associated LS represents a distinct subtype with unique molecular and clinical characteristics.
Salwa Ben Yahia, Anne‐Sophie van der Werf‐'t Lam, Madalina Cabuta, Maartje Nielsen, Noah C. Helderman   +4 more
wiley   +1 more source

Radiomics-based model for predicting neoadjuvant therapy response in esophageal cancer: Limitations and suggestions. [PDF]

World J Gastrointest Oncol
Zhao ZX.
europepmc   +1 more source

Single versus repeated intravenous oncolytic reovirus infusions: Implications for immune modulation and rationalised scheduling of therapy in hepatocellular carcinoma

International Journal of Cancer, EarlyView.
What's New? Oncolytic viruses are a promising immunotherapeutic approach against many malignancies. However, it is unclear whether repeated doses have improved therapeutic value or may trigger greater side effects, especially in patients with hepatocellular carcinoma whose liver is chronically damaged.
Karen J. Scott, Emma J. West, Rebecca J. Brownlie, Fay Ismail, Christy Ralph, Thomas Heineman, Matt Coffey, Alan A. Melcher, Alison Taylor, Salvatore Papa, Adel Samson   +10 more
wiley   +1 more source

Optimising response assessment to neoadjuvant therapy in rectal cancer to reduce the incidence of ypT0N0 resection. [PDF]

Int J Colorectal Dis
Hew J, Mohtashami A, Mastrocostas K, Skinner T, De Silva K, Pavlakis N, Hruby G, Evans J, Salama Y, Kneebone A, Chang KH.   +10 more
europepmc   +1 more source

Oxaliplatin‐induced neuropathy after total neoadjuvant therapy for rectal cancer: Dose–response relationship and impact on quality of life

International Journal of Cancer, EarlyView.
What's New? Oxaliplatin serves a key role in the treatment of rectal cancer, though it is a significant cause of chemotherapy‐induced peripheral neuropathy. As total neoadjuvant therapy, in which all therapy is given before surgery, has become more common, understanding neuropathy has grown increasingly important. This study examined neuropathy and its
Georg W. Wurschi, Andreas Hinz, Melanie Schneider, Jan‐Niklas Becker, Bernd Frerker, Samuel M. Vorbach, Felix Ehret, Markus Diefenhardt, Fabian Schunn, Maria‐Elena von Gruben, Marcel Büttner, Elgin Hoffmann, Alexander Rühle, Josephine Beier, Simone Ferdinandus, Maike Trommer, Ezgi Ceren Sahin, Julian Hlouschek, Kynann Aninditha, Daphne Schepers von Ohlen, Justus Kaufmann, Alina Depardon, Hai Minh Ha, Christopher Kessler, Adrianna Cieslak, Simon Trommer, Alexander Fabian, Florian Rißner, Maximilian Römer, Klaus Pietschmann   +29 more
wiley   +1 more source

Gastrointestinal Toxicity and Clinical Predictors of Total Neoadjuvant Therapy in Rectal Cancer: A Real-World Retrospective Study. [PDF]

Life (Basel)
Bratu LD, Stovicek PO, Ciurea AM, Mehedințeanu AM, Berisha TC, Schenker RA, Dicianu AM, Stamulescu C, Paitici Ș, Mogoantă SȘ, Schenker M.   +10 more
europepmc   +1 more source

Adherens junction protein expression is associated with poor response to neoadjuvant FLOT chemotherapy and pro‐inflammatory tumor microenvironment in esophageal adenocarcinoma

International Journal of Cancer, EarlyView.
What's New? Esophageal adenocarcinoma (EAC) is an aggressive cancer with poor survival and variable response to perioperative chemotherapy. Although histopathological features correlate with outcomes, the relationship specifically between adherens junction (AJ) protein expression and treatment response in EAC remains uncertain.
Bastian Grothey, Heike Löser, Tillmann Bedau, Wolfgang Schröder, Christiane J. Bruns, Thomas Zander, Max Krämer, Reinhard Büttner, Alexander Quaas   +8 more
wiley   +1 more source